source
- STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head studyEli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.STAT · 13d ago↗ source
- Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight lossEli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expect…BioSpace · 13d ago↗ source
- Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetesEli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabete…